Matching articles for "trichloroacetic acid"
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • April 27, 2026; (Issue 1753)
This review includes recommendations for the
treatment of common sexually transmitted infections
(STIs) other than HIV and viral hepatitis in nonpregnant
adolescents and adults. Some of the indications...
This review includes recommendations for the
treatment of common sexually transmitted infections
(STIs) other than HIV and viral hepatitis in nonpregnant
adolescents and adults. Some of the indications and
dosages included here have not been approved by
the FDA.
Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
The Medical Letter on Drugs and Therapeutics • July 21, 2025; (Issue 1733)
Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class
nitric oxide-releasing agent, has been approved
by the FDA for topical treatment of molluscum
contagiosum in patients ≥1 year old. It is the...
Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class
nitric oxide-releasing agent, has been approved
by the FDA for topical treatment of molluscum
contagiosum in patients ≥1 year old. It is the second
drug to become available in the US for treatment
of molluscum contagiosum and the first that can
be applied by the patient or caregiver at home;
cantharidin 0.7% solution (Ycanth), which is applied
by a healthcare professional, was approved earlier for
use in patients ≥2 years old.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • June 27, 2022; (Issue 1653)
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • July 3, 2017; (Issue 1524)
The text and tables that follow include recommendations
for management of sexually transmitted
infections (STIs) other than HIV and viral hepatitis.
Some of the indications and dosages recommended
here have...
The text and tables that follow include recommendations
for management of sexually transmitted
infections (STIs) other than HIV and viral hepatitis.
Some of the indications and dosages recommended
here have not been approved by the FDA.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • October 1, 2010; (Issue 98)
The drugs of choice for treatment of non-HIV viral
infections and their dosages are listed in Tables 1-6 on
the pages that follow. Some of the indications and
dosages recommended here have not been...
The drugs of choice for treatment of non-HIV viral
infections and their dosages are listed in Tables 1-6 on
the pages that follow. Some of the indications and
dosages recommended here have not been approved
by the FDA. Vaccines used for the prevention of viral
infections are discussed in another issue of Treatment
Guidelines.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • July 1, 2010; (Issue 95)
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric...
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. The drugs of choice, their dosages and alternatives are listed in a table that begins on page 54. A table listing the adverse effects of some of these antimicrobials begins on page 58.
Veregen: A Botanical for Treatment of Genital Warts
The Medical Letter on Drugs and Therapeutics • February 25, 2008; (Issue 1280)
The FDA has approved the marketing of sinecatechins (Veregen - Bradley/Medigene), a botanical drug product, for treatment of external genital and perianal warts. Sinecatechins is a water extract of green tea...
The FDA has approved the marketing of sinecatechins (Veregen - Bradley/Medigene), a botanical drug product, for treatment of external genital and perianal warts. Sinecatechins is a water extract of green tea leaves from Camellia sinensis. It is a mixture of catechins and other green tea components.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • September 1, 2007; (Issue 61)
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric...
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. Guidelines are available from the US Centers for Disease Control and Prevention (CDC) with detailed recommendations for treatment of these diseases.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • October 1, 2004; (Issue 26)
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric...
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. Guidelines are available from the US Centers for Disease Control and Prevention (CDC) with detailed recommendations for treatment of these diseases (MMWR Recomm Rep 2002; 51, RR-6:1). New guidelines are expected soon.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • September 24, 1999; (Issue 1062)
Many infections can be transmitted during sexual contact. The text and tables [in this article] are limited to treatment of non-HIV infections associated primarily with sexual...
Many infections can be transmitted during sexual contact. The text and tables [in this article] are limited to treatment of non-HIV infections associated primarily with sexual transmission.
Podofilox For Genital Warts
The Medical Letter on Drugs and Therapeutics • December 13, 1991; (Issue 859)
Podofilox 0.5% solution (Condylox - Oclassen) was recently approved by the US Food and Drug Administration for treatment of (condylomata acuminata). The drug requires a prescription, but is labeled for...
Podofilox 0.5% solution (Condylox - Oclassen) was recently approved by the US Food and Drug Administration for treatment of (condylomata acuminata). The drug requires a prescription, but is labeled for application by the patient. Similar topical solutions previously available for this indication are approved only for application by the physician.
Interferon Treatment of Genital Warts
The Medical Letter on Drugs and Therapeutics • July 15, 1988; (Issue 770)
Recombinant interferon alfa-2b (Intron A - Schering) was recently approved by the US Food and Drug Administration (FDA) for intralesional treatment of genital warts (condylomata acuminata). Interferon was...
Recombinant interferon alfa-2b (Intron A - Schering) was recently approved by the US Food and Drug Administration (FDA) for intralesional treatment of genital warts (condylomata acuminata). Interferon was previously available only for treatment of hairy-cell leukemia (Medical Letter, 28:78, 1986).
